Medical Condition News

RSS

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

One Lambda Inc., a leading manufacturer and supplier of quality products and technology for the HLA transplant community, and Luminex Corporation have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA).

From Luminex 8 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

Psychotic depression: the reason for treatment failure with antidepressants

A new study shows that patients with depression who also have psychotic-like symptoms, feelings of being persecuted, or believing others are plotting against them or hearing voices are less likely to respond to antidepressants. The study also showed that bipolar disorder does not appear to be associated with treatment resistance in patients with depression as believed earlier.

7 Dec 2010

Cognitively-impaired human research subjects need better protection

Practices for protecting human research subjects with Alzheimer’s disease and other conditions that make them incapable of giving informed consent are widely variable and in need of more concrete ethical and legal guidance, according to a study in IRB: Ethics & Human Research.

7 Dec 2010

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists from the Mayo Clinic performed sheathless transradial percutaneous coronary intervention (PCI) to remedy complex lesions, achieving a 90% success rate with no radial complications. Standard guiding catheters were used during the procedure. Details of this novel approach—overcoming the last hurdle to greater adoption of transradial PCI in the U.S.—are published in the December issue of Catheterization and Cardiovascular Intervention, the official journal of The Society for Cardiovascular Angiography and Interventions.

7 Dec 2010

European summit agrees that lifestyle change is the only answer to heart disease

‘Some progress, but the big challenges remain’. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).

7 Dec 2010

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.

7 Dec 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Abbott and Bristol-Myers Squibb Company today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.

7 Dec 2010

$Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL$

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

7 Dec 2010

Mental Health Research Network receives grant to create data resource for mental health researchers

Ask anyone: There must be better ways to treat mental health problems. Treatment hinges on research. But traditional research is slow-and so expensive that it can't even ask many pressing questions in mental health. And findings from academic settings may not apply to patients or clinicians in the real world of health care.

7 Dec 2010

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

7 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark.

7 Dec 2010

$Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010$

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology Annual Meeting being held December 4-7 in Orlando, Florida.

7 Dec 2010

$Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma$

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

7 Dec 2010

OXIS introduces ErgoFlex for relief of joint pain

OXIS International, Inc. announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health.

7 Dec 2010

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP (R-CHOP) chemotherapy, improved remission status of adult patients with diffuse large B-cell lymphoma (DLBCL), a form of aggressive lymphoma.

7 Dec 2010

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months.

7 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Medical Condition News

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

New sensitive blood test could determine unrecognized heart disease

Psychotic depression: the reason for treatment failure with antidepressants

Cognitively-impaired human research subjects need better protection

Sheathless transradial intervention highly successful in treating complex lesions

European summit agrees that lifestyle change is the only answer to heart disease

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Mental Health Research Network receives grant to create data resource for mental health researchers

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

John Theurer Cancer Center presents research findings at ASH meeting

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

OXIS introduces ErgoFlex for relief of joint pain

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News